The Global Oncology Biosimilars Market is expected to grow at 18.5% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...
The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...
Fresenius’s growing pipeline of autoimmune and oncology biosimilars has several molecules in early and late-stage development. Indications Ustekinumab products may increase the risk of infections and ...
The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...
Tiffany Meng, PharmD, an oncology pharmacist, UCSF Health, discusses how pharmacists help mitigate financial toxicity for ...
The FDA has accepted Amneal’s biologics licensing application for two biosimilars referencing Prolia and Xgeva.
Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline in 2024, with several candidates entering late ...
Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback